Massachusetts Financial Services Co. MA Lowers Stake in Thermo Fisher Scientific Inc. $TMO

Massachusetts Financial Services Co. MA decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,342,780 shares of the medical research company’s stock after selling 53,252 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Thermo Fisher Scientific were worth $949,904,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TMO. Brighton Jones LLC increased its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 1st quarter. Victory Capital Management Inc. now owns 171,037 shares of the medical research company’s stock valued at $85,108,000 after purchasing an additional 911 shares during the last quarter. Verdence Capital Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 12.1% during the 1st quarter. Verdence Capital Advisors LLC now owns 4,233 shares of the medical research company’s stock worth $2,106,000 after buying an additional 456 shares during the last quarter. Finally, Graypoint LLC boosted its holdings in Thermo Fisher Scientific by 10.2% in the first quarter. Graypoint LLC now owns 2,705 shares of the medical research company’s stock valued at $1,346,000 after acquiring an additional 250 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president owned 21,152 shares in the company, valued at $12,144,420.80. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 52,341 shares of company stock valued at $29,204,998. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.2%

NYSE:TMO opened at $579.12 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The business’s 50-day simple moving average is $527.90 and its 200 day simple moving average is $467.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market cap of $217.58 billion, a price-to-earnings ratio of 33.46, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the company posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.